NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to alleged misstatements regarding the development of its prostate cancer drug TLX591 and deficiencies in its third-party manufacturing processes, leading to significant investor losses [2][3][6]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][6]. - The SEC is reportedly questioning the accuracy of Telix's development disclosures, while the FDA rejected a Biologics License Application (BLA) due to serious deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][6]. Allegations of Misrepresentation - The complaint claims that Telix and its executives materially overstated the progress of their therapeutic candidates and misrepresented the reliability of their supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, contradicting the company's claims of significant progress and global manufacturing capabilities [3][6]. Investor Impact - The cumulative effect of the regulatory disclosures has led to substantial financial losses for investors who purchased Telix's American Depositary Shares (ADSs) during the class period from February 21, 2025, to August 28, 2025 [6]. - Following the final regulatory news, Telix's ADSs experienced a sharp decline, highlighting the impact of the alleged misstatements on investor confidence [2][6].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=180007&from=3 CLASS PE ...

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=179984&from=4 CLASS PERIO ...

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy (EBRT). EBRT is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typi ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals made materially false and misleading statements regarding its prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the progress made with its therapeutic candidates and the quality of its supply chain and partners [3]. - As a result of these misstatements, the company's statements about its business, operations, and prospects were deemed materially false and misleading [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to stock inflation [5].

Core Viewpoint - The article discusses a securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misrepresentations regarding the development of its therapeutic candidates and supply chain issues, with a significant stock decline following regulatory setbacks [2][3]. Regulatory Failures - The lawsuit highlights two major regulatory events that allegedly corrected market perceptions of Telix's business: - On July 22, 2025, Telix disclosed an SEC subpoena related to its prostate cancer therapeutic candidates, which raised concerns about misleading disclosures on drug development progress [4]. - On August 28, 2025, the FDA rejected the Zircaix application, citing deficiencies in Chemistry, Manufacturing, and Controls (CMC) and documented Form 483 deficiencies at third-party manufacturers [4]. Stock Impact - Following these regulatory revelations, Telix's American Depositary Shares (ADSs) experienced a sharp decline, with a total stock drop of 21% after the final regulatory news [2][4]. Legal Issues - The complaint raises key legal issues, including whether Telix made misleading disclosures regarding drug development progress and whether the company concealed foundational weaknesses in its third-party supply chain and manufacturing processes [4]. Investor Actions - Hagens Berman, the law firm leading the litigation, is actively advising investors who purchased TLX ADSs during the class period and suffered losses due to undisclosed supply chain and therapeutic progress flaws [5]. Important Dates - The deadline for investors to move the court for appointment as lead plaintiff in the lawsuit is January 9, 2026 [1][6].